Our Pricing

Is Wegovy Semaglutide? Understanding the Active Ingredient

Is Wegovy semaglutide? Yes, Wegovy is the brand name for semaglutide 2.4mg, a GLP-1 receptor agonist licensed specifically for chronic weight management in the UK. Manufactured by Novo Nordisk, Wegovy contains the same active pharmaceutical ingredient as Ozempic, but at a higher therapeutic dose optimised for weight loss rather than type 2 diabetes management.

Is Wegovy Semaglutide? The Active Ingredient Explained

When patients ask 'is Wegovy semaglutide?', they're seeking clarity on the relationship between the brand name and the active drug. Wegovy is indeed semaglutide - specifically, it's a once-weekly subcutaneous injection containing semaglutide at doses ranging from 0.25mg to 2.4mg [1]. The medication is identical in molecular structure to the semaglutide used in Ozempic, but Wegovy is licensed by the MHRA exclusively for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related comorbidities.

Semaglutide belongs to the GLP-1 (glucagon-like peptide-1) receptor agonist class, mimicking a naturally occurring hormone that regulates appetite and food intake. In the landmark STEP clinical trial programme, participants using semaglutide 2.4mg achieved an average weight reduction of 15.3% over 68 weeks, compared to 2.6% with placebo [2]. This evidence formed the basis for Wegovy's UK approval and demonstrates why understanding that Wegovy is semaglutide matters for patients evaluating evidence-based weight loss options.

How Is Wegovy Semaglutide Different from Other Semaglutide Products?

While confirming that Wegovy is semaglutide answers the basic question, patients often need clarification on how it differs from other semaglutide formulations available in the UK. Ozempic contains semaglutide at lower doses (0.25mg, 0.5mg, 1mg) and is licensed exclusively for type 2 diabetes, not weight management. Wegovy's dosing schedule escalates to the full 2.4mg maintenance dose, which clinical trials identified as optimal for sustained weight loss [3].

The distinction matters for prescribing purposes - UK prescribers can only issue Wegovy for weight management indications, and the medication requires clinical assessment to confirm eligibility. At Cured Pharmacy, our UK-registered clinical team evaluates each patient's BMI, medical history, and weight-related health conditions before approving treatment. This ensures that when you receive Wegovy semaglutide, it's prescribed appropriately and safely under GPhC-regulated protocols.

Wegovy Semaglutide Dosing Schedule

Understanding that Wegovy is semaglutide also means recognising its specific titration protocol. Treatment begins at 0.25mg weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance dose. This gradual escalation minimises gastrointestinal side effects - the most common adverse reactions reported in clinical trials - whilst allowing the body to adapt to semaglutide's appetite-suppressing effects [4].

Is Wegovy Semaglutide Safe? UK Clinical Evidence

Patients questioning whether Wegovy is semaglutide often want reassurance about the medication's safety profile. As a prescription-only medicine regulated by the MHRA, semaglutide 2.4mg has undergone rigorous clinical evaluation. The STEP trials enrolled over 4,500 participants and monitored safety outcomes across 68 weeks of treatment, establishing a well-characterised adverse event profile [2].

The most frequently reported side effects of Wegovy semaglutide include nausea (44% of participants), diarrhoea (30%), and vomiting (24%), with most cases classified as mild to moderate and diminishing over time [1]. Serious adverse events were rare and comparable to placebo groups. However, semaglutide carries contraindications for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, which is why clinical assessment by a UK prescriber is mandatory before starting treatment.

Is Wegovy Semaglutide Available at the Cheapest UK Price?

Now that we've established Wegovy is semaglutide, cost becomes a practical consideration for UK patients. At Cured Pharmacy, Wegovy semaglutide is available from £69.00 per dose - the cheapest UK price for this MHRA-licensed weight loss treatment. This transparent pricing includes your medication, free clinical assessment by our UK-registered prescribers, and discreet next-day delivery across the United Kingdom.

New patients benefit from £20 off their first order using code Weightlossnew, reducing the initial cost to £69.00. Unlike some providers who advertise low prices but add consultation fees or delivery charges later, our pricing is upfront and comprehensive. Every Wegovy prescription requires clinical approval from our superintendent pharmacist Tarun Kumar (GPhC 2233073) or our prescribing team, ensuring you receive genuine UK-licensed semaglutide with full regulatory oversight.

Wegovy Semaglutide Price Comparison Across UK Providers

When comparing whether Wegovy is semaglutide worth the investment, UK patients should evaluate total treatment costs including clinical fees. Many providers charge separately for consultations, prescriptions, and delivery, making headline prices misleading. At Cured Pharmacy, the £69.00 price represents the complete service - no hidden fees, no subscription lock-ins, and the flexibility to adjust or pause treatment as clinically appropriate with your prescriber's guidance.

How Does Wegovy Semaglutide Work for Weight Loss?

Understanding that Wegovy is semaglutide naturally leads to questions about its mechanism of action. Semaglutide activates GLP-1 receptors in the brain's appetite regulation centres, particularly the hypothalamus, reducing hunger signals and increasing feelings of satiety after meals [3]. This neurohormonal effect means patients typically consume fewer calories without the conscious restriction required by traditional dieting.

Additionally, Wegovy semaglutide slows gastric emptying, prolonging the sensation of fullness after eating. Clinical trial participants reported reduced food cravings and better control over portion sizes - subjective improvements that correlated with objective weight loss measurements [2]. The medication doesn't increase metabolism or burn fat directly; rather, it facilitates a sustainable caloric deficit by making appetite management significantly easier for most patients.

Is Wegovy Semaglutide Right for You? UK Eligibility Criteria

Confirming that Wegovy is semaglutide is just the first step - determining eligibility requires clinical assessment. NICE guidelines recommend semaglutide 2.4mg for adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. Patients must also be willing to engage with lifestyle interventions including dietary modification and increased physical activity.

At Cured Pharmacy, our online clinical assessment takes under three minutes and evaluates your medical history, current medications, and weight loss goals. Our UK prescribers review each application individually, ensuring Wegovy semaglutide is clinically appropriate and safe for your specific circumstances. Treatment is subject to prescriber approval, and we provide ongoing support throughout your weight management journey, with the option to adjust dosing or address side effects through our clinical team.

Starting Wegovy Semaglutide Treatment at Cured Pharmacy

Once approved, your first Wegovy semaglutide prescription is dispensed from our GPhC-registered pharmacy (9012511) with full patient information leaflets and injection technique guidance. We supply genuine Novo Nordisk Wegovy pens with built-in needles for convenient once-weekly administration. If you experience any concerns during treatment, our pharmacist-led team is available via phone on (+44) 116 4646009 to provide expert advice on managing side effects or optimising your dosing schedule in consultation with your prescriber.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
3. Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756. [accessed 15 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.